I
Iovance Biotherapeutics
T-cell-based immunotherapy products for the treatment of cancer
About Iovance Biotherapeutics
Iovance Biotherapeutics, Inc. is a late-stage biotechnology company focused on developing novel T-cell based cancer immunotherapies. The company specializes in Tumor Infiltrating Lymphocytes (TIL) technology, which harnesses a patient's immune system to target and eliminate heterogeneous solid tumors. Iovance's TIL therapies offer unique benefits, including single treatment protocols without the need for maintenance or follow-up therapy, and broad-spectrum antigen specificity, making them suitable for various solid tumor cancers.
Read full description
Iovance operates primarily in the immuno-oncology market, serving patients with advanced cancer conditions. The company's business model revolves around the development, manufacturing, and commercialization of its proprietary TIL therapies. Revenue is generated through the sale of these therapies, as well as potential partnerships and licensing agreements with other pharmaceutical companies.
Iovance is also investing in infrastructure with the construction of the Iovance Cell Therapy Center (iCTC) in Philadelphia, PA, which aims to be a state-of-the-art cell therapy manufacturing facility. This facility will enhance the company's production capabilities and support the scaling of its innovative treatments.
At a glance
- Founded
- 2007
- Headquarters
- New York City, United States
- Listing
- IPO 2010
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tierThoroughbred$100M+ revenue
Latest news
Press, funding announcements and product moves mentioning Iovance Biotherapeutics.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later3 investors entered at this stage
Frazier Healthcare Partners- BRBroadfin
OrbiMed
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
106 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Iovance Biotherapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Iovance Biotherapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.